CoChat

Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease

Casper, Corey, Chaturvedi, Shalini, Munshi, Nikhil, Wong, Raymond, Qi, Ming, Schaffer, Michael, Bandekar, Rajesh, Hall, Brett, van de Velde, Helgi, Vermeulen, Jessica, Reddy, Manjula, van Rhee, Frits · 2015 · Clinical Cancer Research

The DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.

Abstract

PURPOSE: Siltuximab (IL6 antibody) is approved for the treatment of multicentric Castleman disease (MCD). Effects of IL6 inhibition on the inflammatory milieu accompanying MCD have not been characterized. EXPERIMENTAL DESIGN: Trends in inflammatory- and anemia-associated markers, measured over the course of a placebo-controlled study of siltuximab (11 mg/kg q3w) in patients with MCD (n = 79), were characterized. RESULTS: Baseline IL6 and C-reactive protein (CRP) levels were significantly correlated (r = 0.708; P < 0.0001). CRP levels decreased (median, 92%) by cycle 1 day 8 (C1D8), remaining suppressed during siltuximab treatment while remaining stable in the placebo group. There were no associations between baseline CRP or IL6 and MCD symptom burden, histologic subtype, ethnicity, maximum CRP decrease, and response parameters. A hemoglobin response (change ≥ 15 g/L at week 13) was observed with siltuximab (61%; P = 0.0002). Median hepcidin decrease from baseline at C1D8 with siltuximab was 47% versus median 11% increase with placebo. Maximum post-baseline changes in hepcidin levels among siltuximab recipients were correlated with maximum changes for hemoglobin (r = -0.395; P = 0.00607), total iron-binding capacity (TIBC; r = -0.354; P = 0.01694), and ferritin (r = 0.599; P = 0.0001). Greater median changes from baseline in ferritin, hemoglobin, and TIBC were observed in anemic siltuximab-treated patients. CONCLUSIONS: IL6 neutralization with siltuximab resulted in sustained CRP suppression and improvement of anemia, in part, by hepcidin pathway inhibition.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-15-0134

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 33 references

Cited by

See all 97

Metadata

Authors
Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., Reddy, M., & van Rhee, F.
Affiliations
  • Fred Hutch Cancer Center (US)
  • 2Janssen Research & Development, Spring House, Pennsylvania.
  • Harvard University (US)
  • Chinese University of Hong Kong (HK)
  • 5Janssen Research & Development, Beerse, Belgium.
  • Janssen (Netherlands) (NL)
  • 7Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
Corresponding author
Casper, Corey
Venue
Clinical Cancer Research
Published
2015-09-30
Volume
21
Issue
19
Pages
4294-4304
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2120581070
Cited by
97
References
36
Citations by year
2026: 5 · 2025: 6 · 2024: 12 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 8 · 2019: 7 · 2018: 14 · 2017: 12 · 2016: 4 · 2015: 5
FWCI
5.10
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphadenopathy Diagnosis and Analysis
Keywords
siltuximab, multicentric Castleman disease, IL-6 inhibition, anemia, hepcidin, C-reactive protein, ferritin, total iron binding capacity, inflammatory markers, hemoglobin response
MeSH terms
Interleukin-6 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, C-Reactive Protein, Erythrocyte Indices, Female, Castleman Disease, Humans, Iron, Male, Middle Aged, Biomarkers, Interleukin-6, Treatment Outcome, Young Adult, Hepcidins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0134
The paper
Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., Reddy, M., & van Rhee, F. (2015). Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0134

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.